Showing 881 - 900 results of 2,627 for search '"Hematology"', query time: 0.05s Refine Results
  1. 881
  2. 882

    Development and validation of predictive models of early immune effector cell–associated hematotoxicity by Emily C. Liang, Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz-Maldonado, Aya Albittar, Natalie Wuliji, Ryan Basom, Yein Jeon, Qian Wu, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Mohamed Sorror, Joshua A. Hill, Noam E. Kopmar, Rahul Banerjee, Andrew J. Cowan, Damian Green, Ajay K. Gopal, Christina Poh, Mazyar Shadman, Alexandre V. Hirayama, Brian G. Till, Erik L. Kimble, Lorenzo Iovino, Aude G. Chapuis, Folashade Otegbeye, Ryan D. Cassaday, Filippo Milano, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

    Published 2025-02-01
    “…Therefore, we performed comprehensive univariate analyses to identify factors associated with severe (grade 3-4) early ICAHT (eICAHT) in 691 patients who received commercial or investigational CAR T-cell therapy for hematologic malignancies. In univariate logistic regression, preinfusion factors associated with severe eICAHT included disease type (acute lymphoblastic leukemia), prelymphodepletion (pre-LD) blood counts including absolute neutrophil count (ANC), lactate dehydrogenase (LDH), and inflammatory (C-reactive protein [CRP], ferritin, and interleukin-6 [IL-6]) and coagulopathy biomarkers (D-dimer). …”
    Get full text
    Article
  3. 883
  4. 884
  5. 885
  6. 886

    Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis by Haihang Zhang, Junhao Zeng, Fangling Zhang, Jing Liu, Long Liang

    Published 2025-01-01
    “…The dysregulation of BCL11A disrupts downstream molecular pathways, contributing to the development of several hematological malignancies, particularly leukemias. This review provides a comprehensive overview of the role of BCL11A in normal and malignant hematopoiesis, details the hematological disorders associated with its dysregulation and explores the current therapeutic strategies targeting this transcription factor.…”
    Get full text
    Article
  7. 887
  8. 888
  9. 889
  10. 890
  11. 891
  12. 892
  13. 893
  14. 894
  15. 895
  16. 896
  17. 897
  18. 898

    Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia by Tong-Yoon Kim, Gi-June Min, Young-Woo Jeon, Seung-Ah Yahng, Seok-Goo Cho, Jong-Mi Lee, Myungshin Kim, Ki-Seong Eom

    Published 2025-01-01
    “…We compared the impact of bicytopenia with those of other hematologic conditions. <b>Results</b>: The 5-year overall survival (OS) and 5-year progression-free survival (PFS) for all patients were 84.4% and 68.3%, respectively. …”
    Get full text
    Article
  19. 899

    Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation by Yao-Chung Liu, Sheng-Hsuan Chien, Nai-Wen Fan, Ming-Hung Hu, Jyh-Pyng Gau, Chia-Jen Liu, Yuan-Bin Yu, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Cheng-Hwai Tzeng, Po-Min Chen, Jin-Hwang Liu

    Published 2016-01-01
    “…The cure of hematologic disorders by allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with major complications resulting in poor outcome, including graft-versus-host disease (GVHD), relapse, and death. …”
    Get full text
    Article
  20. 900